Latest Conference Articles

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer

March 19th 2022, 4:26pm

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

Ociperlimab/Tislelizumab Combo Under Exploration in Previously Treated Recurrent or Metastatic Cervical Cancer

March 18th 2022, 7:14pm

The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

March 18th 2022, 6:55pm

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Real-World Analysis Shows Survival Benefit With Second-Line PARP Maintenance Over Active Surveillance in Ovarian Cancer

March 18th 2022, 5:38pm

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Precision Medicine Takes Hold of Prostate Cancer Management

March 16th 2022, 4:00pm

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022, 2:00pm

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022, 1:00pm

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

March 15th 2022, 5:00pm

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022, 1:00pm

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

March 14th 2022, 2:13pm

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022, 10:11pm

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

March 5th 2022, 5:20pm

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach

March 5th 2022, 1:39pm

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer

March 5th 2022, 11:00am

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.

Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development

March 4th 2022, 10:24pm

CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.

Neoadjuvant Immunotherapy/Chemotherapy Combos Gain in Prominence for Early-Stage TNBC

March 4th 2022, 7:40pm

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Breast Cancer Research Begins With Curiosity

March 4th 2022, 6:50pm

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

ctDNA Assays Open the Door for Earlier Detection, Intervention in Breast Cancer

March 4th 2022, 5:00pm

Pat W. Whitworth, MD, explains how data from past studies are informing the use of circulating tumor DNA and talks about the potential of these assays to guide treatment decisions in patients with breast cancer.

Loprinzi Shares Top Concerns, Best Practices for Treatment-Related Toxicity Management in Breast Cancer

March 4th 2022, 4:00pm